Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05828927
Other study ID # LCCC2242
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 15, 2023
Est. completion date July 1, 2025

Study information

Verified date May 2024
Source UNC Lineberger Comprehensive Cancer Center
Contact Jesse Kovacs
Phone 919-962-5356
Email encompasscarolina@unc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study explores the feasibility, acceptability, and preliminary efficacy of a social support intervention in cancer caregivers who live in rural communities. Cancer caregivers need support, especially when they live at a distance from healthcare centers. enCompass Carolina is a social support intervention, that supports caregivers by helping them find and use new sources of support. The purpose of this study is to test and receive feedback about the program.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date July 1, 2025
Est. primary completion date July 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria Inclusion criteria for caregivers In order to participate in this study a subject must meet all of the eligibility criteria outlined below. 1. English-speaking. 2. Ability to provide written or electronic informed consent to participate in the study. 3. Subject is willing and able to comply with study procedures based on the judgment of the investigator or protocol designee. 4. Age = 18 years at the time of consent. Identify as an informal (unpaid) caregiver for a rural-dwelling adult with a stage II-IV solid tumor or any hematologic malignancy in active treatment (see eligibility criteria for patients). Inclusion criteria for subjects with cancer In order to participate in this study a subject must meet all of the eligibility criteria outlined below. 1. Their identified caregiver is enrolled in the study 2. English-speaking. 3. Ability to provide written or electronic informed consent to participate in the study. 4. Subjects are willing and able to comply with study procedures based on the judgment of the investigator or protocol designee. 5. Age = 18 years at the time of consent. Have a diagnosis of stage II-IV solid tumor or any hematologic malignancy receiving active treatment s, not including hormonal therapy 7. Live in a rural area according to the USDA's Rural/Urban Commuting Area (RUCA) score of >4. Exclusion Criteria Exclusion criteria for caregivers 1. Unable to complete self-report instruments due to illiteracy, neurologic illness, inability to speak or read English, or other causes; 2. Existence of another co-morbid disease, which in the opinion of the investigator, prohibits participation in the protocol; 3. Participation in the intervention development phase of this intervention. Exclusion criteria for subjects with cancer 1. Unable to complete self-report instruments due to illiteracy, neurologic illness, inability to speak or read English, or other causes; 2. Existence of another co-morbid disease, which in the opinion of the investigator, prohibits participation in the protocol; 3. Their caregiver does not enroll in the study or withdraws consent

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Eco-mapping tool
The web application allows caregivers to visually identify and organize their existing social network (family, friends, community of worship, and others) to assist with their support needs, tailored to their context. For each of the six support social support domains (in-home, informational, communication, financial, emotional and spiritual, transportation (e.g., emotional, informational, practical), the enCompass web application prompts the individual to identify members of their network. After completing each domain, caregivers are presented with a visual social support
Caregiver-coach study visits
Caregivers engage in up to 8 manualized, telephone/videoconference visits with a trained caregiver coach. The caregiver coach uses the study manual and interview guide to provide support for caregiver support-seeking and problem-solving.

Locations

Country Name City State
United States UNC Lineberger Chapel Hill North Carolina

Sponsors (2)

Lead Sponsor Collaborator
UNC Lineberger Comprehensive Cancer Center The Duke Endowment

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Study feasibility - caregiver enrollment Study feasibility will be measured by caregiver enrollment rates, defined as the proportion of eligible caregivers approached about the study who consent to participate. 8 weeks
Primary Study feasibility - Caregiver intervention engagement Study feasibility will be measured by caregiver intervention engagement, defined as the proportion of enrolled caregiver subjects who receive at least one intervention visit. 8 weeks
Secondary Intervention acceptability-qualitative Intervention acceptability will be measured using the Acceptability of the Intervention Measure (AIM) survey scores.
AIM is a survey questionnaire that includes 4 questions. Response Scale: 1 = Completely disagree, 2 = Disagree, 3 = Neither agree nor disagree, 4 = Agree, 5 = Completely agree. Scoring Instructions: Scales can be created for each measure by averaging responses. Scale values range from 1 to 5. No items need to be reverse-coded.
4 weeks, 8 weeks
Secondary Intervention acceptability-quantitative Intervention acceptability will be evaluated using thematic analysis of post-intervention semi-structured interviews. 4 weeks, 8 weeks
Secondary Caregiver self-efficacy Caregiver self-efficacy will be measured using the Coping Self-Efficacy Scale (CSES).
The CSES is a 26-item measure of one's confidence in performing coping behaviour when facing life challenges. It measures the use of problem-focused coping, receiving of social support and stopping unpleasant emotions and thoughts. Scores range from not at all confident=0 to very confident=100. A score of 0 means 'extremely low self efficacy' and a score of 100 means 'extremely high self efficacy'.
Baseline, 4 weeks, 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients